Privia Health (NASDAQ:PRVA) just turned in a quarter that checked every box management set for itself, and then raised the bar again for the rest of the year. On the company’s August 6 earnings call, CEO Parth Mehrotra and CFO David Mountcastle laid out a business adding doctors, patients, and cash at a pace that has held for nine straight years. The question is whether the market is pricing in the streak continuing.
Bull Case: A Growth Engine Still Humming
Privia’s numbers move together. Implemented providers grew 10.1% year-over-year to 5,644, adding 109 physicians in the quarter alone, while value-based attributed lives climbed 19.2%. That combination pushed practice collections up 12.4% to $970 million in the second quarter and 13.4% to $1.88 billion for the first half. Adjusted EBITDA rose 29% to $37.4 million, with margin as a share of care margin expanding 310 basis points to 28.3%, a sign the business is getting more profitable as it scales, not just bigger.
In late May, Privia entered New Jersey, its 25th state, through a partnership with the Urology Group of Bergen County covering 25 clinicians. Commercial attributed lives rose 11.7% to 942,000, while CMS Medicare lives jumped 55%. The company now oversees an estimated $15.7 billion in total medical spend across more than 130 value-based programs, and gross provider retention has averaged 98% over the past three years. Management raised 2026 guidance across practice collections, care margin, GAAP revenue, platform contribution, and EBITDA, with attributed lives already tracking above the prior high end.
Bear Case: Cash Timing And Policy Are Wildcards
The growth story comes with a few strings attached. Privia became a full cash taxpayer this year, and management expects only 70% to 80% of full-year adjusted EBITDA to convert to free cash flow, a figure that assumes the company collects a significant chunk of its 2025 shared savings payments by year-end. That assumption now has a complication: CMS proposed changes to the Medicare Shared Savings Program for performance year 2025 that could delay final reconciliation results until November, which management says could create an atypical year-end cash flow pattern even though the accrual impact looks minimal.
The company also holds $412 million in cash with no debt, which is a comfortable cushion, but its raised guidance still assumes no additional business development activity, meaning any acquisitions would be upside not yet baked in.
Wall Street Watches The Growth Story
Hedge fund ownership ticked up from 29 funds to 30 in the most recent quarter, a modest gain rather than a rush. Short interest sits at 4.45% of float, which points to limited organized skepticism around the stock. As of August 13, Privia trades at a forward P/E of 24.63, a multiple that assumes the earnings growth investors just saw continues rather than fades.
Where The Story Goes From Here
Privia’s second quarter gave bulls plenty to point to: double-digit growth in providers, patients, and profitability, plus guidance that keeps climbing. The bear case is thinner and more about timing than fundamentals, centered on how CMS’s proposed MSSP changes play out and whether cash flow lands where management expects by year-end. For the growth trajectory to keep justifying its valuation, the provider and attribution gains need to keep compounding at this pace.
While we acknowledge the risk and potential of PRVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
